Turning tumors into vaccines: co-opting the innate immune system.
about
Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell VaccinationTranslational implications of tumor heterogeneitySelective RNA targeting and regulated signaling by RIG-I is controlled by coordination of RNA and ATP binding.From computational modelling of the intrinsic apoptosis pathway to a systems-based analysis of chemotherapy resistance: achievements, perspectives and challenges in systems medicine.Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.Efficient solid-phase synthesis of pppRNA by using product-specific labeling.Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine.CD8 engineered cytotoxic T cells reprogram melanoma tumor environment.Interleukin-17 and type 17 helper T cells in cancer management and research.Worldwide malaria incidence and cancer mortality are inversely associated.Intratumoral immunization: a new paradigm for cancer therapy.Strategies to relieve immunosuppression in pancreatic cancer.Intratumoral immunotherapy for melanoma.Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut.Pattern recognition receptors: immune targets to enhance cancer immunotherapy.PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Tumor suppressor activity of RIG-I.Discriminating self from non-self in nucleic acid sensing.Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitorDelivering safer immunotherapies for cancer.Dopaminergic Regulation of Innate Immunity: a Review.Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand.Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationAntigen-Directed Fabrication of a Multifunctional Nanovaccine with Ultrahigh Antigen Loading Efficiency for Tumor Photothermal-Immunotherapy.A minimal RNA ligand for potent RIG-I activation in living mice.Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.
P2860
Q26765345-EC9B5630-69FF-47C4-9B03-54EEA2FEA1EBQ26822823-F488AB73-BCD3-403E-9677-666ABDBD3485Q33554200-58281F0F-DD1A-4EFE-AC5A-2254019D1B19Q33720383-F026286C-D3AA-460B-ADD9-2CB0FA2C9B05Q34654430-BCB67FB7-E892-43A6-9F7E-1D1F95A1C4BEQ35131625-396FE3FE-AB8C-4057-8641-5A2575F00C02Q35695115-9D1E22FB-9DCB-4A87-8D91-BE54A9DD535AQ36821069-969837F8-27E4-4C94-90E1-D13EF86A143BQ37031654-3934C0AF-CF66-439C-85FA-1D8EE3814924Q37640572-0E82743F-14A9-4AA4-BCEB-EABD7D792754Q37691837-F252C655-2C0B-450C-AE89-197EE9C3D1F7Q38445328-38C5633D-5FCB-4AE6-B3FC-E65860D96CA1Q38518518-8C76FCF2-0B3B-4ADF-9756-9375CDC0F840Q38683312-447E974A-5AB9-4BCB-8EF3-F818ADDB034EQ38690773-B079CE0D-3B5D-40A3-891B-EA7DF9ADE30EQ38692217-E3A1D754-F57C-4570-B473-6ED05DDAD142Q38769021-11602E79-EBE4-4AF2-A4A8-C86B58AD597DQ38866734-D6C2F100-5AB6-45E5-B5B3-AAA1DF9A1DE0Q38907820-D82A5B5A-51FD-4544-B592-4E67A259934BQ38954685-A52F966C-A806-40D2-9272-B0D29B87629FQ39330984-B5859712-22E1-4EB3-8CB9-AE8FF6233662Q39348712-CC64F797-7C28-4BDB-98DD-B55D4AE04E2EQ40757843-F964DF75-9917-43C1-9A97-BC314AC7EAE3Q41182217-5A303081-AC85-4DFA-A1B2-770660CBC429Q42586718-5CE0B10C-BCA5-48F1-B01A-3BDC202F68FEQ42702294-A9DECE0E-B7A9-4636-AC55-B4EFFB0BAB23Q48273406-DC231220-F10F-44E1-A0DD-2CE23FEBBFA9Q50335102-D10C320C-08B7-468D-B47E-DCFF5E7C83AAQ55508841-0D366134-A117-43D9-B5A4-CB4837735506
P2860
Turning tumors into vaccines: co-opting the innate immune system.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Turning tumors into vaccines: co-opting the innate immune system.
@en
type
label
Turning tumors into vaccines: co-opting the innate immune system.
@en
prefLabel
Turning tumors into vaccines: co-opting the innate immune system.
@en
P1433
P1476
Turning tumors into vaccines: co-opting the innate immune system.
@en
P2093
Jasper G van den Boorn
P356
10.1016/J.IMMUNI.2013.07.011
P407
P577
2013-07-01T00:00:00Z